Finally, the Israeli study involved practically exclusively BRCA1/2 founder mutations associated with cancer risk in Ashkenazi Jewish populations [13] and, therefore, was by definition different from BRCA1/2 mutations in Austrian populations. The gene discussed is BRCA1; the disease is cancer.